Literature DB >> 17487262

Botulinum toxin type A inhibits rat pyloric myoelectrical activity and substance P release in vivo.

Yi-Ping Hou1, Yong-Ping Zhang, Yan-Feng Song, Chun-Min Zhu, Yin-Chun Wang, Gui-Lin Xie.   

Abstract

The effect of botulinum toxin type A (BTX-A) on rat pyloric myoelectrical activity in vivo and the content and distribution of substance P (SP) in pylorus were investigated, respectively, with electromyography, radioimmunoassay, and immunohistochemistry. A pair of electrodes for recording pyloric myoelectrical activity and a guide cannula for drug injection were implanted into the pylorus. The changes of pyloric myoelectrical activity were recorded followed vehicle, 10, 20, and 40 U/kg body mass of BTX-A injection. Pyloric tissues were dissected for radioimmunoassay and immunohistochemistry after recording. The 3 dosages of BTX-A injections caused the reduction of slow wave of pyloric myoelectrical activity in amplitude but not in frequency and the diminishment of spike activity in amplitude and spike burst. The inhibitory effect of 20 U/kg BTX-A was significantly different from that of 10 U/kg (p<0.05), but not from the effect of 40 U/kg administration (p>0.05). After BTX-A intrasphincteric injection, SP content was reduced in the pylorus, and cell number of SP-immunoreactivity was decreased more in myenteric nerve plexus of circular muscle and in mucosa of pylori. In conclusion, BTX-A inhibits pyloric myoelectrical slow activity in amplitude and spike activity and weakens pyloric smooth muscle contractility depending on threshold of dose or concentration. BTX-A-induced inhibition of pyloric myoelectrical activity implies a mechanism of inhibiting SP release from the autonomic and enteric nervous terminals in the pylorus.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17487262     DOI: 10.1139/y07-018

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  12 in total

1.  Factors associated with symptom response to pyloric injection of botulinum toxin in a large series of gastroparesis patients.

Authors:  Radoslav Coleski; Michelle A Anderson; William L Hasler
Journal:  Dig Dis Sci       Date:  2009-12       Impact factor: 3.199

Review 2.  Endoscopic treatment of gastroparesis.

Authors:  Thomas R McCarty; Tarun Rustagi
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

3.  Botulinum toxin and gastrointestinal tract disorders: panacea, placebo, or pathway to the future?

Authors:  Brian E Lacy; Kirsten Weiser; Abigail Kennedy
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-04

4.  The Effect of Botulinum Toxin in Experimental Hypertrophic Pyloric Stenosis.

Authors:  Mehmet Sarıkaya; İlhan Çiftci; Nejat Ünlükal; Tamer Sekmenli; Metin Gündüz
Journal:  J Laparoendosc Adv Surg Tech A       Date:  2021-11-16       Impact factor: 1.878

5.  Substance P is essential for maintaining gut muscle contractility: a novel role for coneurotransmission revealed by botulinum toxin.

Authors:  Cuiping Li; Maria-Adelaide Micci; Karnam S Murthy; Pankaj Jay Pasricha
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-04-03       Impact factor: 4.052

Review 6.  Botulinum neurotoxin for pain management: insights from animal models.

Authors:  Flaminia Pavone; Siro Luvisetto
Journal:  Toxins (Basel)       Date:  2010-12-21       Impact factor: 4.546

7.  Preferential entry of botulinum neurotoxin A Hc domain through intestinal crypt cells and targeting to cholinergic neurons of the mouse intestine.

Authors:  Aurélie Couesnon; Jordi Molgó; Chloé Connan; Michel R Popoff
Journal:  PLoS Pathog       Date:  2012-03-15       Impact factor: 6.823

Review 8.  Emerging opportunities for serotypes of botulinum neurotoxins.

Authors:  Zhongxing Peng Chen; J Glenn Morris; Ramon L Rodriguez; Aparna Wagle Shukla; John Tapia-Núñez; Michael S Okun
Journal:  Toxins (Basel)       Date:  2012-11-07       Impact factor: 4.546

9.  The Inhibitory Effect of Botulinum Toxin Type A on Rat Pyloric Smooth Muscle Contractile Response to Substance P In Vitro.

Authors:  Yu-Feng Shao; Jun-Fan Xie; Yin-Xiang Ren; Can Wang; Xiang-Pan Kong; Xiao-Jian Zong; Lin-Lan Fan; Yi-Ping Hou
Journal:  Toxins (Basel)       Date:  2015-10-15       Impact factor: 4.546

10.  Botulinum toxin type a therapy in migraine: preclinical and clinical trials.

Authors:  Yu-Feng Shao; Yi Zhang; Peng Zhao; Wen-Jun Yan; Xiang-Pan Kong; Lin-Lan Fan; Yi-Ping Hou
Journal:  Iran Red Crescent Med J       Date:  2013-10-05       Impact factor: 0.611

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.